<DOC>
	<DOCNO>NCT00868790</DOCNO>
	<brief_summary>This study assess safety efficacy MK-3577 . The primary efficacy hypothesis , 4 week treatment , either morning ( AM ) administration evening ( PM ) administration MK-3577 provide superior reduction 24-hour weighted mean glucose ( WMG ) level compare placebo ( PLA ) . The primary safety hypothesis MK-3577 well tolerate compare placebo .</brief_summary>
	<brief_title>A Study Safety Efficacy MK-3577 Participants With Type 2 Diabetes Mellitus ( MK-3577-009 )</brief_title>
	<detailed_description>This 4-period/5-treatment crossover study . Each period 4 week . The 5 treatment consist MK-3577 10 mg daily ( QD ) AM , MK-3577 6 mg QD evening ( PM ) , MK-3577 25 mg twice daily ( BID ) , metformin 1000 mg BID , placebo MK-3577/placebo metformin . Participants randomize one 14 treatment sequence arm . A subset participant group domicile ( stay overnight ) select clinical site Baseline , Week 4 ( end Period 1 ) , Week 8 ( end Period 2 ) undergo 24-hr blood sample .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Participant type 2 diabetes Participant either take antihyperglycemic medication last 10 week OR take single oral antihyperglycemic medication ( Peroxisome ProliferatorActivated Receptor gamma [ PPARg ] agonist ) OR take lowdose combination oral antihyperglycemic medication ( PPARg agonist ) dose less equal 50 % maximum dose Female participant unable child Participant history type 1 diabetes ketoacidosis Participant treat PPARg agonist last 12 week Participant treat insulin last 12 week Participant prescription lipidmodifying drug therapy last 12 week Participant history coronary artery disease Participant stroke transient ischemic attack Participant congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>